 | • レポートコード：MRC2303L103 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、257ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に7,201.32百万ドルであった世界の生物製剤受託開発市場規模が2022年に8,064.04百万ドルとなり、2027年までに年平均12.23％拡大して14,394.00百万ドルに達すると予測されています。本書では、生物製剤受託開発の世界市場を対象に総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、由来別（哺乳類、微生物）分析、種類別（分子療法薬、モノクローナル抗体、組換えタンパク質、ワクチン）分析、疾患別（心血管疾患、血液疾患、免疫疾患、腫瘍）分析、製品サービス別（細胞株開発、プロセス開発）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの構成でまとめております。なお、本書に掲載されている企業情報には、AbbVie, Inc.、Abzena Plc.、AGC Biologics、Ajinomoto Co., Inc.、Avid Bioservices, Inc.、Binex Co., Ltd.、Boehringer Ingelheim GmbH、Cambrex Corporation、Catalent, Inc.、Emergent BioSolutions Inc.、Fujifilm Holding Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の生物製剤受託開発市場規模：由来別 - 哺乳類由来生物製剤の市場規模 - 微生物由来生物製剤の市場規模 ・世界の生物製剤受託開発市場規模：種類別 - 分子療法薬の市場規模 - モノクローナル抗体の市場規模 - 組換えタンパク質の市場規模 - ワクチンの市場規模 ・世界の生物製剤受託開発市場規模：疾患別 - 心血管疾患における市場規模 - 血液疾患における市場規模 - 免疫疾患における市場規模 - 腫瘍における市場規模 ・世界の生物製剤受託開発市場規模：製品サービス別 - 細胞株開発の市場規模 - プロセス開発の市場規模 ・世界の生物製剤受託開発市場規模：地域別 - 南北アメリカの生物製剤受託開発市場規模 アメリカの生物製剤受託開発市場規模 カナダの生物製剤受託開発市場規模 ブラジルの生物製剤受託開発市場規模 ... - アジア太平洋の生物製剤受託開発市場規模 日本の生物製剤受託開発市場規模 中国の生物製剤受託開発市場規模 インドの生物製剤受託開発市場規模 韓国の生物製剤受託開発市場規模 台湾の生物製剤受託開発市場規模 ... - ヨーロッパ/中東/アフリカの生物製剤受託開発市場規模 イギリスの生物製剤受託開発市場規模 ドイツの生物製剤受託開発市場規模 フランスの生物製剤受託開発市場規模 ロシアの生物製剤受託開発市場規模 ... - その他地域の生物製剤受託開発市場規模 ・競争状況 ・企業情報 |
The Global Biologics Contract Development Market size was estimated at USD 7,201.32 million in 2021 and expected to reach USD 8,064.04 million in 2022, and is projected to grow at a CAGR 12.23% to reach USD 14,394.00 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biologics Contract Development to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Source, the market was studied across Mammalian and Microbial.
Based on Type, the market was studied across Molecular Therapy, Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
Based on Disease Indication, the market was studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
Based on Product Service, the market was studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biologics Contract Development market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biologics Contract Development Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biologics Contract Development Market, including AbbVie, Inc., Abzena Plc., AGC Biologics, Ajinomoto Co., Inc., Avid Bioservices, Inc., Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions Inc., Fujifilm Holding Corporation, JSR Life Sciences, LLC, Lonza Group AG, ProBioGen AG, Recipharm AB, Rentschler Biotechnologie GmbH, Samsung Biologics Co., Ltd., Siegfried Holding AG, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., and WuXi Biologics Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biologics Contract Development Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biologics Contract Development Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biologics Contract Development Market?
4. What is the competitive strategic window for opportunities in the Global Biologics Contract Development Market?
5. What are the technology trends and regulatory frameworks in the Global Biologics Contract Development Market?
6. What is the market share of the leading vendors in the Global Biologics Contract Development Market?
7. What modes and strategic moves are considered suitable for entering the Global Biologics Contract Development Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Favorable government regulations for clinical trials
5.1.1.2. Rising adoption of contract manufacturing for research & development
5.1.1.3. Inclination towards the usage of advanced technologies for biologic development
5.1.2. Restraints
5.1.2.1. Associated high cost of biologics contract development
5.1.3. Opportunities
5.1.3.1. Penetration of drug discoveries all over the globe
5.1.3.2. Enhanced production flexibility in the biopharmaceutical industry
5.1.4. Challenges
5.1.4.1. Concern related to limited adoption due to lack of knowledge
5.2. Cumulative Impact of COVID-19
6. Biologics Contract Development Market, by Source
6.1. Introduction
6.2. Mammalian
6.3. Microbial
7. Biologics Contract Development Market, by Type
7.1. Introduction
7.2. Molecular Therapy
7.3. Monoclonal Antibodies
7.4. Recombinant Proteins
7.5. Vaccines
8. Biologics Contract Development Market, by Disease Indication
8.1. Introduction
8.2. Cardiovascular Disorders
8.3. Hematological Disorders
8.4. Immunological Disorders
8.5. Oncology
9. Biologics Contract Development Market, by Product Service
9.1. Introduction
9.2. Cell Line Development
9.3.1. Mammalian
9.3.2. Microbial
9.3. Process Development
9.4.1. Downstream
9.4.2.1. Impurity, Isolation, & Identification
9.4.2.2. Pharmaceutical Analysis
9.4.2.3. Physicochemical Characterization
9.4.2. Upstream
9.4.3.1. Mammalian
9.4.3.2. Microbial
10. Americas Biologics Contract Development Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biologics Contract Development Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biologics Contract Development Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. AbbVie, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abzena Plc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. AGC Biologics
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Ajinomoto Co., Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Avid Bioservices, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Binex Co., Ltd.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Boehringer Ingelheim GmbH
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cambrex Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Catalent, Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Emergent BioSolutions Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Fujifilm Holding Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. JSR Life Sciences, LLC
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Lonza Group AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. ProBioGen AG
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Recipharm AB
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Rentschler Biotechnologie GmbH
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Samsung Biologics Co., Ltd.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Siegfried Holding AG
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Thermo Fisher Scientific, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Toyobo Co. Ltd.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. WuXi Biologics Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing